RPE65-associated Leber congenital amaurosis (LCA), a type of early-onset RP (Fig. 3), has been shown to be highly amenable to treatment with sub-retinal gene therapy in mice, dogs and humans (6, 7, S11). The gene discussed is RPE65; the disease is Leber congenital amaurosis.